Newsroom

The CGT sector is making significant strides, highlighted by the FDA approval of the first CRISPR therapeutic. Experts, including Josh Ludwig, Global Director, Commercial Operations, ScaleReady, predict continued growth and innovation in 2024 and beyond. Key challenges include manufacturing capacity, standardization, and delivery systems. However, advancements in technology and partnerships between developers and manufacturers offer promising solutions.

Bio-Techne, Wilson Wolf, and CellReady awarded a $300,000 G-Rex Grant to Stanford Medicine's LCGM for CAR-T cell therapy manufacturing. The grant is part of a $20 million initiative to support CGT development. Eligible recipients receive supplies, support, and discounts. Stanford Medicine LCGM plans to use the grant for a Phase I trial and potency testing. Feldman from Stanford Medicine LCGM expressed the grant's importance for future clinical trials. Wilson from Wilson Wolf praised Stanford University's reputation for innovation.

MaxCyte and ScaleReady have partnered for the G-Rex Grant Program, which aims to accelerate cell and gene therapy development. The program offers resources, tools, and expertise to recipients. MaxCyte's electroporation technology and ScaleReady's manufacturing solutions are key components of the program. The goal is to reduce barriers to entry for CGT companies and expedite the development of life-saving therapies.

In this episode of Voices of Biotech podcast, ScaleReady's Josh Ludwig and Germfree's Carol Houts dive into the critical need for a more sustainable and standardized manufacturing model to improve access to life-saving therapies. Discover how decentralized manufacturing can revolutionize the industry, addressing challenges like talent shortages and drug supply issues. Learn why sustainability isn't just about the environment but also about patient care and health equity.

Cell and gene therapy companies struggle to scale up production. ScaleReady’s Global Director Josh Ludwig argues they lack essential manufacturing expertise. Unlike industries like automotive and medical devices, CGT firms often ignore proven methods. To succeed, they must hire manufacturing experts and effectively use automation.

ISCT 2024 showcased the latest in cell and gene therapy (CGT). A key focus was on industry sustainability. Josh Ludwig from ScaleReady emphasized the need for operational efficiency over simply expanding space. Optimizing processes like inventory management is crucial for reducing costs and environmental impact.

The surge in CAR-T and gene therapy approvals is driving pharma investment in cell therapy manufacturing. Josh Ludwig, ScaleReady's Global Director of Commercial Operations, discusses the success of therapies like Carvykti underscores the need for robust manufacturing. This growing demand will fuel further investment in both therapies and the supporting manufacturing technologies.

Digital transformation in pharma needs careful planning, according to Josh Ludwig of ScaleReady. User-friendly technology and streamlined operations are key. Technology providers must partner with pharma companies to ensure successful implementation.

ScaleReady, in collaboration with Wilson Wolf, Bio-Techne, and CellReady, has launched a ‘G-Rex’ grant program aimed at advancing CGTs.

Industry leaders are uniting to drive the future of cell and gene therapy manufacturing. Experts like Josh Ludwig of ScaleReady are at the forefront of implementing automation and digital solutions to overcome complex challenges in the sector. From streamlining operations to accelerating time-to-market, these advancements are poised to revolutionize the industry.

The final installment of "The Top Line" series dives deep into the cutting-edge world of cell and gene therapy manufacturing. Join host Fraiser Kansteiner, Josh Ludwig and other industry experts as they explore innovative production approaches and discuss how to overcome the challenges of bringing these life-saving therapies to market.

CAR-T therapy has promise but manufacturing is slow and expensive. In this article, ScaleReady's Josh Ludwig suggests CAR-T manufacturing can learn from the auto industry's assembly-line approach to improve efficiency and make these therapies more accessible.